UTRS (Minerva Surgical) Total Current Assets: $40.00 Mil (As of Sep. 2023)


What is Minerva Surgical Total Current Assets?

Minerva Surgical UTRS -99.00% Total Current Assets is $40.00 Mil as of Sep. 2023.

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Minerva Surgical's total current assets for the quarter that ended in Sep. 2023 was $40.00 Mil.


Minerva Surgical  (OTCPK:UTRS) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Minerva Surgical's Liquidation Value for the quarter that ended in Sep. 2023 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=11.125-52.53+0.75 * 7.569+0.5 * 18.183
=-26.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Minerva Surgical Total Current Assets Related Terms


Minerva Surgical Total Current Assets Historical Data

* Premium members only.

The historical data trend for Minerva Surgical's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Minerva Surgical Total Current Assets Chart

Minerva Surgical Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Total Current Assets
43.81 45.42 75.00 36.12

Minerva Surgical Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Total Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 49.20 36.12 54.11 46.08 40.00

Minerva Surgical Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Minerva Surgical's Total Current Assets for the fiscal year that ended in Dec. 2022 is calculated as

Minerva Surgical's Total Current Assets for the quarter that ended in Sep. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Frequently Asked Questions Learn more about Total Current Assets →
What does a Total Current Assets of $40.00 Mil mean?
Minerva Surgical (UTRS) has a Total Current Assets of $40.00 Mil as of Sep. 2023. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Minerva Surgical and its competitors.
Is Minerva Surgical's Total Current Assets too high?
Minerva Surgical's current Total Current Assets is $40.00 Mil.
How does Minerva Surgical's Total Current Assets compare to PAVM and ELUT?
Minerva Surgical's Total Current Assets of $40.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Assets for a Medical Devices & Instruments company?
A good Total Current Assets depends on the Medical Devices & Instruments industry context. However, Total Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Assets mean?
A high Total Current Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Minerva Surgical and its competitors. Minerva Surgical's current Total Current Assets is $40.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minerva Surgical stock overvalued right now?
Minerva Surgical (UTRS) has a current Total Current Assets of $40.00 Mil. The current Total Current Assets is $40.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Assets calculated?
Total Current Assets is calculated from a company's financial statements. For Minerva Surgical (UTRS), the current Total Current Assets is $40.00 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Minerva Surgical Business Description

Address 4255 Burton Drive, Santa Clara, CA, USA, 95054
Minerva Surgical Inc is a medical device company that develops therapeutic devices that treat abnormal uterine bleeding in a minimally invasive manner. The Company operates and manages its business as one reportable and operating segment, which is the business of research, development, and sale of therapeutic devices for abnormal uterine bleeding treatment.